文献速递临床试验与 GCP

甲氨蝶呤单药与甲氨蝶呤联合来氟米特治疗银屑病关节炎的随机对照试验方案

Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).
PubMed 文献 · Trials · 2020-02-10

COMPLETE-PsA是一项随机、安慰剂对照、双盲临床试验,纳入78例未使用过改善病情抗风湿药的活動性银屑病关节炎患者,1:1随机接受甲氨蝶呤联合来氟米特或甲氨蝶呤联合安慰剂治疗。主要终点为16周时两组间银屑病关节炎疾病活动度评分(PASDAS)的差异,旨在比较联合治疗与单药治疗的有效性和安全性。

要点

  • COMPLETE-PsA首次以随机双盲安慰剂对照设计评估MTX联合LEF治疗PsA。
  • 纳入78例DMARD初治的活动性PsA患者,按PASDAS≥5.4分层随机。
  • 主要终点为16周时PASDAS组间差异,调整基线PASDAS。

核心结论

  • 该试验旨在比较MTX联合LEF与MTX单药治疗PsA的有效性和安全性,为治疗策略提供证据。

研究设计与样本

  • 随机、安慰剂对照、双盲临床试验,纳入78例DMARD初治的活动性PsA患者,1:1随机分组并按PASDAS≥5.4分层。

关键数值与推荐

  • 干预组接受MTX 25 mg每周一次(口服或皮下)联合LEF 20 mg每日,对照组接受相同MTX但以安慰剂替代LEF。
  • 主要终点为16周时PASDAS的组间差异,调整基线PASDAS。
  • 关键次要终点包括DAPSA评分变化、皮肤评分、附着点炎评分、指趾炎评分、肿胀/压痛关节计数、MDA达标比例及ACR 20/50/70应答率。
  • 安全性、功能和生活质量通过HAQ、PSAID、SF-12评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Both methotrexate (MTX) and leflunomide (LEF) are registered and regularly prescribed as first-line treatments for the use in patients with psoriatic arthritis (PsA) and they are occasionally used in combination. However, evidence about their individual, and especially combined efficacy, in PsA is lacking. The aim of this study is to compare the effectiveness and safety of MTX and LEF combination therapy to MTX monotherapy in patients with PsA. METHODS: COMPLETE-PsA is a randomized, placebo-controlled, double-blind clinical trial. Disease-modifying antirheumatic drug (DMARD)-untreated patients (n = 78) with clinical diagnosis of active (i.e. ≥2 swollen joints) PsA will be randomized 1:1 (stratified for high disease activity, Psoriatic Arthritis Disease Activity Score [PASDAS] ≥ 5.4) to the combination or monotherapy. The intervention group receives MTX 25 mg (oral or subcutaneous) once weekly plus LEF 20 mg daily, and the control group receives the same but with placebo instead of LEF daily. Primary endpoint is between-group difference in PASDAS at 16 weeks, adjusted for baseline PASDAS. Key secondary parameters include between-group comparisons in change in Disease Activity in Psoriatic Arthritis (DAPSA) score, skin score, enthesitis score, dactylitis score, and swollen/tender joint count, as well as the proportion of patients fulfilling minimal disease activity (MDA), American College of Rheumatology (ACR) 20/50/70 response criteria at week 16. Furthermore, safety, function and quality of life (Health Assessment Questionnaire [HAQ], Psoriatic Arthritic Impact of Disease [PSAID], Short Form 12 [SF-12]) will be assessed. DISCUSSION: This is, to our knowledge, the first randomized, placebo-controlled, double-blind clinical trial assessing the effectiveness of MTX and LEF combination therapy in patients with PsA. The study will provide important information for treatment strategies and treatment recommendations. TRIAL REGISTRATION: Dutch Trial Register NTR7632 (3 December 2018). CMO NL66544.091.18 (19 November 2018).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Mulder MLM, Vriezekolk JE, den Broeder N, et al. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA). Trials. 2020. PMID: 32041657. doi:10.1186/s13063-020-4097-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。